Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hisamitsu Pharmaceutical Co ( (JP:4530) ) has issued an update.
Hisamitsu Pharmaceutical’s board has resolved to convene an extraordinary shareholders’ meeting on April 17, 2026 to vote on a share consolidation, abolition of share unit provisions, and amendments to its articles of incorporation. These corporate actions are part of a broader management buyout transaction led by Taiyo Kosan aimed at taking the company private following a tender offer that ran from January 7 to February 19, 2026.
As a result of the planned share consolidation and related procedures, Hisamitsu’s common stock will meet delisting criteria on the Tokyo, Nagoya and Fukuoka exchanges. The shares are expected to be designated as securities under supervision from April 17 to May 10, 2026, and delisted on May 11, 2026, after which they will no longer trade on the Prime, Premier or Main markets, materially affecting liquidity and public market access for existing shareholders.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen7130.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japan-based pharmaceutical company listed on the Tokyo, Nagoya and Fukuoka exchanges. The company is known for developing and manufacturing prescription and over-the-counter medicines, with a particular focus on pain relief and topical treatments in both domestic and overseas markets.
Average Trading Volume: 574,079
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen440.7B
For detailed information about 4530 stock, go to TipRanks’ Stock Analysis page.